KYTX vs RMD · $488.8M cap vs P/E 29, rev $5.65B
Kyverna Therapeutics, Inc. Common Stock (KYTX) versus ResMed Inc (RMD) — a side-by-side from cached financials, not a winner call.
Kyverna Therapeutics, Inc. Common Stock (KYTX) is a biotechnology company listed on NASDAQ.
ResMed Inc (RMD) is a medical instruments & supplies company listed on US.
KYTX does not have a complete income-statement cache yet.
Latest reported RMD revenue for 2026-06-30 was $5.65B. Net income was $1.52B. Revenue was up 9.9% from 2025-06-30 to 2026-06-30. RMD currently screens at market cap $37.68B and trailing P/E 28.8.
KYTX currently screens at market cap $488.8M. RMD currently screens at market cap $37.68B and trailing P/E 28.8.
Not investment advice. Open the KYTX and RMD stock pages for the full models.
Not investment advice.